BioXcel Therapeutics, Inc. (BTAI)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$17.2M
Cash & Equivalents
$11.8M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$25M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
DEXMEDETOMIDINE HYDROCHLORIDE
IGALMI |
APPROVED | Agitation, Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Alcohol Use Disorder (AUD), Bipolar Disorder, Bipolar Disorder I, Bipolar Disorder II, Bipolar I Disorder, Bipolar II Disorder, Cancer of Pancreas, Cancer of the Pancreas, Delirium, Dementia, Dexmedetomidine, Metastatic Pancreatic Ductal Adenocarcinoma, Neoplasms, Pancreatic, Neuroendocrine Tumors, Opioid Use Disorder, Opioid Withdrawal, Pancreas Cancer, Pancreatic Cancer, Post Traumatic Stress Disorder (PTSD), Prostate Cancer, Psychomotor Agitation, Schizo Affective Disorder, Schizoaffective Disorder, Schizophrenia, Schizophrenia Agitation, Schizophreniform Disorders, Schizophreniform; Schizophrenic, Small Cell Carcinoma |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-11-14 | Pdufa | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05712707 | Sublingual Dexmedetomidine for Treating Opioid Withdrawal | PHASE2 | Active Not Recruiting | 160 |
| NCT05558982 | BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | PHASE2 | Active Not Recruiting | 22 |
| NCT06335407 | Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study | PHASE1 | Recruiting | 10 |
| NCT05025605 | Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder | PHASE1 | Recruiting | 140 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.